Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Achilles Therapeutics Plc (ACHL)
Achilles Therapeutics Plc (ACHL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 55,465
  • Shares Outstanding, K 40,783
  • Annual Sales, $ 0 K
  • Annual Income, $ -71,180 K
  • 60-Month Beta 0.88
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.29
Trade ACHL with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.14
  • Number of Estimates 2
  • High Estimate 0.22
  • Low Estimate -0.51
  • Prior Year -0.61
  • Growth Rate Est. (year over year) +77.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8500 +60.00%
on 01/31/24
1.4300 -4.90%
on 02/22/24
+0.4600 (+51.11%)
since 01/23/24
3-Month
0.7900 +72.15%
on 12/26/23
1.4300 -4.90%
on 02/22/24
+0.5620 (+70.43%)
since 11/22/23
52-Week
0.7402 +83.73%
on 11/16/23
1.4300 -4.90%
on 02/22/24
+0.2100 (+18.26%)
since 02/23/23

Most Recent Stories

More News
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

NetworkNewsWire Editorial Coverage : More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation...

GNPX : 4.36 (-0.91%)
RHHBY : 32.9600 (+1.45%)
JAZZ : 132.28 (+2.98%)
ALXO : 15.85 (-1.25%)
ACHL : 1.3600 (unch)
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

NetworkNewsWire Editorial Coverage : More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation...

GNPX : 4.36 (-0.91%)
RHHBY : 32.9600 (+1.45%)
JAZZ : 132.28 (+2.98%)
ALXO : 15.85 (-1.25%)
ACHL : 1.3600 (unch)
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END

GNPX : 4.36 (-0.91%)
RHHBY : 32.9600 (+1.45%)
JAZZ : 132.28 (+2.98%)
ALXO : 15.85 (-1.25%)
ACHL : 1.3600 (unch)
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

/PRNewswire/ -- More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the...

RHHBY : 32.9600 (+1.45%)
GNPX : 4.36 (-0.91%)
JAZZ : 132.28 (+2.98%)
ALXO : 15.85 (-1.25%)
ACHL : 1.3600 (unch)
Is Achilles Therapeutics (ACHL) Outperforming Other Medical Stocks This Year?

Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and Geron (GERN) have performed compared to their sector so far this year.

ACHL : 1.3600 (unch)
GERN : 1.9600 (-0.51%)
Is Anika Therapeutics (ANIK) Stock Outpacing Its Medical Peers This Year?

Here is how Anika Therapeutics (ANIK) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.

ANIK : 25.89 (+4.27%)
ACHL : 1.3600 (unch)
What Makes Achilles Therapeutics PLC Sponsored ADR (ACHL) a New Buy Stock

Achilles Therapeutics PLC Sponsored ADR (ACHL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near...

ACHL : 1.3600 (unch)
Apellis' (APLS) Empaveli Aids Growth, Stiff Competition a Woe

Apellis' (APLS) lead drug, Empaveli, is approved for treating paroxysmal nocturnal hemoglobinuria. The drug's label expansion studies hold promise. Stiff competition remains an overhang.

AZN : 65.83 (+2.65%)
ATRA : 0.7400 (-5.98%)
APLS : 68.47 (+1.30%)
ACHL : 1.3600 (unch)
Alnylam (ALNY) Gets FDA Approval for Oxlumo Label Expansion

The FDA approves Alnylam's (ALNY) Oxlumo for treating primary hyperoxaluria type 1 to lower urinary oxalate and plasma oxalate levels in pediatric and adult patients.

ALNY : 157.65 (-3.17%)
ATRA : 0.7400 (-5.98%)
ORIC : 11.02 (+8.89%)
ACHL : 1.3600 (unch)
Allogene (ALLO) Begins Phase II Study on Allogeneic CAR T Therapy

Allogene (ALLO) starts the pivotal phase II ALPHA2 study evaluating its allogeneic CAR T therapy, ALLO-501A in patients with relapsed/refractory large B-cell lymphoma.

ATRA : 0.7400 (-5.98%)
ALLO : 4.54 (+4.13%)
ORIC : 11.02 (+8.89%)
ACHL : 1.3600 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Achilles Therapeutics plc is a clinical-stage biopharmaceutical company. It engages in developing precision T cell therapies to treat solid tumors. Achilles Therapeutics plc is based in LONDON.

See More

Key Turning Points

3rd Resistance Point 1.5933
2nd Resistance Point 1.5067
1st Resistance Point 1.4333
Last Price 1.3600
1st Support Level 1.2733
2nd Support Level 1.1867
3rd Support Level 1.1133

See More

52-Week High 1.4300
Last Price 1.3600
Fibonacci 61.8% 1.1665
Fibonacci 50% 1.0851
Fibonacci 38.2% 1.0037
52-Week Low 0.7402

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar